Regarding the Supply of Favipiravir to the UK

News Highlights

It has become clear that the UK government is in discussions with the Japanese government regarding the supply of favipiravir (Avigan), a candidate drug for treating novel coronavirus infections. These discussions are reportedly for the purpose of the UK using the drug in clinical trials. The Japanese government aims to build an international cooperative framework for the supply of favipiravir.

M&A Medical Editorial Department’s Perspective

The news that the UK government has approached the Japanese government for the supply of favipiravir (Avigan) may seem, at first glance, to be solely about international pharmaceutical supply. However, from a medical M&A perspective, it underscores the reality that the traditional “self-contained clinic” management model is becoming obsolete. In particular, it suggests the increasing need for medical corporations struggling with lack of successors to consider external partnerships for future business continuity. As in the case of favipiravir, there may be an increasing number of situations where specific pharmaceuticals, technologies, or international networks become indispensable for the survival and development of medical institutions. The utilization of such external resources, and the business restructuring and partnerships that enable it, could become important options for the management of medical institutions going forward.

Points Raised by This News

• The potential impact of international pharmaceutical supply movements on the business continuity strategies of domestic medical institutions
• An era where access to specific pharmaceuticals and technologies determines the competitiveness and survival of medical institutions
• External partnerships and business restructuring as new solutions for the problem of successor absence
• Implication of the need to shift management models from “self-contained” to “externally partnered”

Practical Questions Arising from This News

• How will the current discussion about favipiravir supply relate to the management of my clinic?
• Will clinics lacking successors be able to access such international pharmaceutical supply chains in the future?
• What kind of external partnerships should I consider now for future business continuity?

If You Feel “Should I Consult?”

Are you concerned about future successor issues or access to specific pharmaceuticals and technologies in your clinic’s management? As exemplified by the favipiravir case, external partnerships could be key to business continuity. At M&A Medical, we propose concrete schemes for options such as third-party succession and business partnerships, looking at your clinic’s current situation and future. Please allow us to hear about your clinic’s situation during a free consultation.

M&A Medical (CentralMedience Inc.) supports the succession of business for medical corporations, hospitals, and clinics on a completely success-fee basis as an M&A support institution certified by the Small and Medium Enterprise Agency. Consultations are accepted with strict confidentiality. Free consultation here